NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NHGRI E-044-2013-1-US-18 OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA US CON 17/024,100 11802283 Issued PDF
NCI E-176-2022-0-PC-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease PCT PCT PCT/EP2020/075948 Expired
NCI E-176-2022-0-US-02 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease US National Stage 17/753,706 Abandoned
NCI E-176-2022-0-CN-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease CN National Stage 202080065098.2 Abandoned
NCI E-176-2022-0-EP-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease EP National Stage 20774960.7 Abandoned
NCI E-036-2021-0-US-01 METHODS FOR TREATING INFECTIONS US 63/079,741 Abandoned
NCI E-176-2022-0-BR-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease BR National Stage BR112022004861 Abandoned
NCI E-176-2022-0-AU-01 Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease AU National Stage 2020349353 Abandoned
NEI E-058-2018-0-AU-04 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS AU National Stage 2019236297 Issued
NCI E-494-2013-0-AU-22 Methods of Preparing Anti-human Papillomavirus Antigen T Cells AU DIV 2020233702 Issued
NEI E-058-2018-0-US-03 Using Machine Learning And/or Neural Networks To Validate Stem Cells And Their Derivatives (2-D Cells And 3-D Tissues) For Use In Cell Therapy And Tissue Engineered Products US National Stage 16/981,531 11531844 Issued PDF
NEI E-058-2018-0-JP-07 USING MACHINE LEARNING AND/OR NEURAL NETWORKS TO
VALIDATE STEM CELLS AND THEIR DERIVATIVES FOR USE IN CELL
THERAPY, DRUG DISCOVERY, AND DIAGNOSTICS 		JP National Stage 2020-549687 Issued
NINDS E-025-2018-1-IE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof IE EP 19716018.7 Issued
NINDS E-025-2018-1-DE-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof DE EP 19716018.7 Issued
NINDS E-025-2018-1-FR-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof FR EP 19716018.7 Issued
NINDS E-025-2018-1-CH-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof CH EP 19716018.7 Issued
NINDS E-025-2018-1-EP-02 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof EP National Stage 19716018.7 Issued
NINDS E-025-2018-1-GB-01 Positive Allosteric Modulators of Dopamine 1 Receptor and Methods of Use Thereof GB EP 19716018.7 Issued
NIAID E-166-2021-0-US-01 Coronavirus Antibodies And Uses Thereof US 63/078,666 Abandoned
NCI E-036-2018-0-KR-04 HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS KR National Stage 10-2020-7026443 Abandoned
NCI E-097-2018-0-SA-14 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SA National Stage 520420134 Abandoned
NCI E-097-2018-0-AE-03 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES AE National Stage P6001291/2020 Pending
NHLBI E-143-2021-1-US-01 TISSUE EXCISION, CUTTING, AND REMOVAL SYSTEMS AND METHODS US 63/077,579 Abandoned
NEI E-227-2018-0-PCT-02 DRUGGABLE TARGET TO TREAT RETINAL DEGENERATION PCT PCT PCT/US2020/050540 Expired
NHGRI E-122-2017-0-PCT-02 CANCER DETECTION AND CLASSIFICATION PCT PCT PCT/US2020/050522 Expired
NCI E-182-2019-2-PCT-01 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER PCT PCT COMB PCT/US2020/050439 Expired
NCI E-097-2018-0-US-16 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES US National Stage 16/980,205 Pending
NCI E-182-2019-2-EP-05 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER EP National Stage 20785624.6 Pending
NCI E-193-2020-0-US-01 RNASEH-ASSISTED DETECTION ASSAY FOR RNA (RADAR) US 63/077,123 Abandoned
NCI E-182-2019-2-CA-03 RECEPTOR TYROSINE KINASE INHIBITORS FOR TREATMENT OF PROTEIN KINASE MODULATION-RESPONSIVE DISEASE OR DISORDER CA National Stage 3153096 Pending
NCI E-494-2013-0-HK-21 Methods of Preparing Anti-human Papillomavirus Antigen T Cells HK EP 42020015851.7 Issued
NCI E-227-2006-5-AU-21 PREVENTION OF TISSUE ISCHEMIA, RELATED METHODS AND COMPOSITIONS AU DIV 2020230283 Issued
NCI E-030-2022-0-PCT-02 Anti-Viral Compositions And Methods Of Making And Using PCT PCT PCT/US2020/050200 Expired
NCI E-097-2018-0-IN-10 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN National Stage 202047039152 Pending
NCI E-097-2018-0-MX-12 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES MX National Stage MX/a/2020/009472 Pending
NCATS E-229-2016-0-US-05 PEPTIDE INHIBITORS OF PHOSPHOGLYCERATE MUTASE AND METHODS OF USE US DIV 17/016,168 Abandoned
NCI E-097-2018-0-CN-06 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CN National Stage 201980018105.0 Pending
NCI E-097-2018-0-CA-05 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES CA National Stage 3093567 Pending
NCI E-097-2018-0-SG-15 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES SG National Stage 11202008796V Pending
NCI E-097-2018-0-ZA-17 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES ZA National Stage 2020/05571 Pending
NCI E-097-2018-0-NZ-13 ANTI-CD33 CHIMERIC ANTIGEN RECEPTORS AND THEIR USES NZ National Stage 767782 Pending
NCI E-167-2019-0-US-01 T CELL PHENOTYPES ASSOCIATED WITH RESPONSE TO ADOPTIVE CELL THERAPY US 63/075,536 Abandoned
NCI E-081-2018-0-US-03 17-BETA-HYDROXYWITHANOLIDES AND USE THEREOF IN TREATING CANCER US National Stage 16/978,442 12018045 Issued PDF
NIDA E-023-2018-0-EP-03 DREADD ACTUATORS EP National Stage 19706192.2 Pending
NIDA E-023-2018-0-GB-01 DREADD ACTUATORS GB EP 19706192.2 Pending
NIDA E-023-2018-0-DE-01 DREADD ACTUATORS DE EP 19706192.2 Pending
NIDA E-023-2018-0-FR-01 DREADD ACTUATORS FR EP 19706192.2 Pending
NCI E-173-2020-0-US-01 T CELL RECEPTORS RECOGNIZING R273C OR Y220C MUTATION IN P53 US 63/074,747 Abandoned
NCI E-162-2014-0-US-09 Human Monoclonal Antibodies (mAbs) Against EphA4 As Candidate Therapeutics US CON 17/012,928 Abandoned
NINDS E-025-2018-1-US-03 POSITIVE ALLOSTERIC MODULATORS OF DOPAMINE 1 RECEPTOR AND METHOD OF USE THEREOF US National Stage 16/977,897 Pending